Sou Hu Cai Jing·2025-07-18 08:53Core Viewpoint - The AI Fund Yinhua Medical Health Quantitative Stock Initiation A (005237) reported a profit of 704,200 yuan in Q2 2025, with a net value growth rate of 3.25% for the period, indicating a positive performance in the medical and healthcare sector [2]. Fund Performance - As of the end of Q2 2025, the fund's scale was 22.77 million yuan [13]. - The fund's unit net value as of July 17 was 1.253 yuan [2]. - The fund's performance over various time frames includes: - 3-month net value growth rate: 12.97%, ranking 47 out of 54 comparable funds [2]. - 6-month net value growth rate: 18.70%, ranking 47 out of 54 comparable funds [2]. - 1-year net value growth rate: 19.99%, ranking 45 out of 53 comparable funds [2]. - 3-year net value growth rate: -15.15%, ranking 29 out of 46 comparable funds [2]. Risk Metrics - The fund's Sharpe ratio over the past three years was -0.1083, ranking 30 out of 46 comparable funds [7]. - The maximum drawdown over the past three years was 39.37%, ranking 24 out of 46 comparable funds, with the largest single-quarter drawdown occurring in Q1 2021 at 25.15% [8]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and healthcare stocks, with a strong emphasis on the innovative drug industry [2]. - The average stock position over the past three years was 89.19%, with a peak of 92.5% at the end of H1 2025 and a low of 85.16% at the end of H1 2024 [11]. Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included: - Heng Rui Medicine - WuXi AppTec - Mindray Medical - BeiGene - East China Pharmaceutical - Kelun Pharmaceutical - Baillie Gifford - Betta Pharmaceuticals - Zai Lab - Kailai Ying [16].